Soluble HLA‐A,‐B,‐C and ‐G molecules induce apoptosis in T and NK CD8+ cells and inhibit cytotoxic T cell activity through CD8 ligation
Open Access
- 20 December 2002
- journal article
- research article
- Published by Wiley in European Journal of Immunology
- Vol. 33 (1) , 125-134
- https://doi.org/10.1002/immu.200390015
Abstract
There is convincing evidence that soluble HLA-A,-B,-C (sHLA-A,-B,-C) and soluble HLA-G (sHLA-G) antigens can induce apoptosis in CD8+ activated T cells although there is scanty and conflicting information about the mechanism(s) by which sHLA-A,-B,-C antigens and sHLA-G antigens induce apoptosis. In this study we have compared the apoptosis-inducing ability of sHLA-A,-B,-C antigens with that of sHLA-G1 antigens in CD8+ T lymphocytes and CD8+ NK cells. Furthermore we have compared the inhibitory effect of sHLA-A,-B,-C antigens and of sHLA-G1 antigens on theactivity of EBV-specific CD8+ cytotoxic T lymphocytes (CTL). sHLA molecules were purified from serum and from the supernatant of HLA class I-negative cells transfected with one gene encoding either classical or non-classical HLA class I antigens. Both classical and non-classical sHLA class I molecules trigger apoptosis in CD8+ T lymphocytes and in CD8+ NK cells, which lack the T cell receptor, and their apoptotic potency is comparable. The binding of sHLA-A,-B,-C and sHLA-G1 molecules to CD8 leads to Fas ligand (FasL) up-regulation, soluble FasL (sFasL) secretion and CD8+ cell apoptosis by Fas/sFasL interaction. Moreover, classical and non-classical sHLA class I molecules inhibit the cytotoxic activity of EBV-specific CD8+ CTL. As the amount ofsHLA-G molecules detectable in normal serum is significantly lower than that of sHLA-A,-B,-C molecules, the immunomodulatory effects of sHLA class I molecules purified from serum are likely to be mainly attributable to classical HLA class I antigens. As far as the potential in vivo relevance of these findings is concerned, we suggest that classical sHLA class I molecules may play a major immunoregulatory role in clinical situations characterized by activation of the immune system and elevated sHLA-A,-B,-C serum levels. In contrast, non-classical HLA class I molecules may exert immunomodulatory effects in particular conditions characterized by elevated sHLA-G levels such as pregnancy and some neoplastic diseases.Keywords
This publication has 29 references indexed in Scilit:
- Soluble human leukocyte antigen-G serum level is elevated in melanoma patients and is further increased by interferon-? immunotherapyCancer, 2001
- A Novel Approach to Antigen-Specific Deletion of CTL with Minimal Cellular Activation Using α3 Domain Mutants of MHC Class I/Peptide ComplexImmunity, 2001
- PURIFIED TRUNCATED RECOMBINANT HLA-B7 MOLECULES ABROGATE CELL FUNCTION IN ALLOREACTIVE CYTOTOXIC T LYMPHOCYTES BY APOPTOSIS INDUCTION1,2Transplantation, 1998
- Elevated serum level of soluble HLA class I antigens in patients with systemic lupus erythematosusArthritis & Rheumatism, 1996
- Serum HLA class I antigens: markers and modulators of an immune response?Immunology Today, 1995
- HETEROGENEOUS DISTRIBUTION OF THE DETERMINANTS DEFINED BY MONOCLONAL ANTIBODIES ON HLA-A AND B ANTIGENS BEARING MOLECULESTransplantation, 1982
- Major histocompatibility antigens: The human (HLA-A,-B,-C) and murine (H-2K, H-2D) class I moleculesCell, 1981
- Production of monoclonal antibodies to group A erythrocytes, HLA and other human cell surface antigens-new tools for genetic analysisCell, 1978
- Soluble HL-A7 Antigen: Localization in the β-Lipoprotein Fraction of Human SerumScience, 1970
- Anti HL-A2 Inhibitor in Normal Human SerumNature, 1970